Читать книгу Biologics, Biosimilars, and Biobetters - Группа авторов - Страница 87

Herceptin^® was developed by Genentech, now a Roche subsidiary, and UCLA's Jonsson Comprehensive Cancer Center.

Indication: HER2+ breast cancer

Manufacturer: Roche

Global Sales in 2017: $7.4 billion

Generic name: Trastuzumab

Launch date: 1998